TARS
Tarsus Pharmaceuticals, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 102 | +3 | 26.51M | $1.67B | +7 | −3 |
| Q1 2026 | 101 | +5 | 27.05M | $1.90B | +10 | −6 |
| Q4 2025 | 97 | 0 | 27.39M | $2.24B | +2 | −1 |
| Q3 2025 | 16 | 0 | 11.66M | $693.15M | +1 | −2 |
| Q2 2025 | 14 | 0 | 10.63M | $430.62M | — | — |
| Q1 2025 | 11 | +2 | 4.92M | $252.88M | +2 | — |
| Q4 2024 | 9 | 0 | 3.55M | $196.55M | — | — |
| Q3 2024 | 8 | 0 | 2.33M | $76.49M | — | — |
| Q2 2024 | 8 | — | 2.46M | $66.86M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 773.24K | — | $21.02M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 773.24K | — | $21.02M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Two Sigma Investments ✦ | 434.34K | — | $11.81M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Millennium Management ✦ | 348.59K | — | $9.47M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 291.27K | — | $7.92M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 291.27K | — | $7.92M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 269.79K | — | $7.33M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 207.49K | — | $5.64M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 207.49K | — | $5.64M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 127.33K | — | $3.46M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 127.33K | — | $3.46M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Wellington Management ✦ | 127.33K | — | $3.46M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Wellington Management ✦ | 127.33K | — | $3.46M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 7.49K | — | $203,660 | 0.0% | n/c | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 7.49K | — | $203,660 | 0.0% | n/c | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 7.49K | — | $203,660 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 252 holders, 45.11M shares, $3.08B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.